Drug class
Central antimuscarinic antiparkinsonian agent
Mechanism of action
Blocks central muscarinic acetylcholine receptors, reducing relative cholinergic overactivity in basal ganglia circuits and improving tremor and rigidity in parkinsonism.
General use cases
- Treatment of parkinsonian symptoms and selected drug-induced extrapyramidal symptoms in countries where bornaprine remains authorised; current availability is limited and anticholinergic risks apply
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
